Recursion Pharmaceuticals Inc的资讯和分析评论

Recursion 2026年第一季度每股收益（EPS）为-0.22美元，超出市场预期的-0.26美元；但营收表现不佳，录得647万美元，远低于市场预期的1628万美元，差距高达60.26%。 受喜忧参半的业绩和营收大幅不及预期的影响，公司股价在盘前交易中下跌1.84%，报3.20美元。 公司将现金运营支出同比削减了30%；并维持6.65亿美元的现金头寸，这将公司财务跑道延长至2028年初。 公司 ...

Morgan Stanley Raises its Price Target on Recursion (RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the 10 Best Penny Stocks to Buy for Long Term. On May 14, 2026, ...

最近搜索 财报 记录 公司 分析师评级 内幕交易 SEC文件 Pro

智通财经APP获悉，招银国际发布研报称，当前AI制药的价值主要体现在早期研发效率的提升上，核心壁垒正从算法转向数据资产。该行认为... Recursion Pharmaceuticals（递归制药）公布了2026年第一季度财报，每股亏损优于市场预期，但营收则大幅低于 ...

Recursion Pharmaceuticals, Inc. Class A

View Recursion Pharmaceuticals, Inc. Class A RXRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Recursion Reports First Quarter Financial Results and Provides Business Update

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid ...

A Look At Recursion Pharmaceuticals (RXRX) Valuation After Clinical Updates And FDA Discussions

Recursion Pharmaceuticals (RXRX) has been in focus after fresh clinical updates on REC-4881 and REC-1245, along with ongoing FDA discussions for a potential registrational pathway, drew attention away ...
CNBC

Recursion Pharmaceuticals CEO explains how AI could make drug development faster and less ...

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...

Recursion Announces Board Transition

Detailed price information for Shandong Molomg Petroleum Machinery Co. Ltd (SHANF) from The Globe and Mail including charting and trades.